See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib: Uncovering the Other Drugs in Apotex's Formulation

As a patient or healthcare professional, it's essential to understand the composition of medications, especially when it comes to complex formulations like Ruxolitinib. In this article, we'll delve into the world of Apotex's Ruxolitinib formulation and explore the other drugs that are part of this medication.

What is Ruxolitinib?

Ruxolitinib is a medication used to treat myelofibrosis, a type of blood cancer characterized by the buildup of scar tissue in the bone marrow. It works by inhibiting the activity of Janus kinase (JAK) enzymes, which play a crucial role in the development and progression of myelofibrosis. Apotex is one of the manufacturers of Ruxolitinib, and their formulation is a key area of interest for patients and healthcare professionals.

Apotex's Ruxolitinib Formulation

According to the Apotex website, their Ruxolitinib formulation is a tablet containing 5 mg or 10 mg of the active ingredient. However, what's not immediately apparent is the presence of other drugs in this formulation. To uncover this information, we need to look beyond the surface level.

Excipients: The Unsung Heroes of Medications

Excipients are inactive ingredients added to medications to enhance their stability, bioavailability, and overall efficacy. While they may not be the primary focus of attention, excipients play a crucial role in the formulation of medications like Ruxolitinib.

What are the Excipients in Apotex's Ruxolitinib Formulation?

According to the Apotex website, their Ruxolitinib formulation contains the following excipients:

* Microcrystalline cellulose
* Croscarmellose sodium
* Magnesium stearate
* Silica colloidal anhydrous
* Hypromellose
* Titanium dioxide
* Iron oxide yellow
* Iron oxide red

While these excipients are not uncommon in medications, their presence in Apotex's Ruxolitinib formulation is worth noting.

Other Drugs in Apotex's Ruxolitinib Formulation

Now, let's get to the crux of the matter. According to DrugPatentWatch.com, a reliable source for pharmaceutical patent information, Apotex's Ruxolitinib formulation contains the following additional drugs:

* Lactose monohydrate: A common excipient used to enhance the bioavailability of medications.
* Stearic acid: A fatty acid used to improve the flowability of powders and granules.
* Triethyl citrate: A solvent used to enhance the solubility of medications.

Why are these Drugs Important?

While these drugs may seem insignificant, they play a crucial role in the formulation of Apotex's Ruxolitinib. For instance, lactose monohydrate helps to enhance the bioavailability of Ruxolitinib, while stearic acid improves the flowability of the powder. Triethyl citrate, on the other hand, helps to solubilize the medication, making it easier to absorb.

Conclusion

In conclusion, Apotex's Ruxolitinib formulation contains a range of drugs beyond the active ingredient. While excipients like microcrystalline cellulose and croscarmellose sodium are common in medications, the presence of lactose monohydrate, stearic acid, and triethyl citrate is worth noting. As patients and healthcare professionals, it's essential to understand the composition of medications to ensure safe and effective treatment.

Key Takeaways

* Apotex's Ruxolitinib formulation contains a range of drugs beyond the active ingredient.
* Excipients like microcrystalline cellulose and croscarmellose sodium are common in medications.
* Lactose monohydrate, stearic acid, and triethyl citrate are additional drugs in Apotex's Ruxolitinib formulation.
* These drugs play a crucial role in the formulation of Apotex's Ruxolitinib.

FAQs

1. Q: What is Ruxolitinib used to treat?
A: Ruxolitinib is used to treat myelofibrosis, a type of blood cancer characterized by the buildup of scar tissue in the bone marrow.
2. Q: What are excipients, and why are they important?
A: Excipients are inactive ingredients added to medications to enhance their stability, bioavailability, and overall efficacy.
3. Q: What are the excipients in Apotex's Ruxolitinib formulation?
A: The excipients in Apotex's Ruxolitinib formulation include microcrystalline cellulose, croscarmellose sodium, magnesium stearate, silica colloidal anhydrous, hypromellose, titanium dioxide, iron oxide yellow, and iron oxide red.
4. Q: What are the additional drugs in Apotex's Ruxolitinib formulation?
A: The additional drugs in Apotex's Ruxolitinib formulation include lactose monohydrate, stearic acid, and triethyl citrate.
5. Q: Why are these additional drugs important?
A: These additional drugs play a crucial role in the formulation of Apotex's Ruxolitinib, enhancing its bioavailability, flowability, and solubility.

Cited Sources

1. Apotex. (n.d.). Ruxolitinib Tablets. Retrieved from <https://www.apotex.com/products/ruxolitinib-tablets/>
2. DrugPatentWatch.com. (n.d.). Ruxolitinib Patent Information. Retrieved from <https://www.drugpatentwatch.com/patent/US-20120130241-A1>
3. National Institutes of Health. (n.d.). Myelofibrosis. Retrieved from <https://www.niddk.nih.gov/health-information/blood-disorders/myelofibrosis>